SymBio Pharmaceuticals - Treakisym has positive DLBCL results
On 5 November 2019, SymBio announced it obtained positive results in its pivotal Phase III clinical trial of Treakisym (bendamustine) in patients...
1.6k Views
902 Views
Japan Pharma - Top Picks
While Gni Group Ltd (2160 JP) is our high risk-high return pick, Mitsubishi Tanabe Pharma (4508 JP) is a contrarian call in anticipation of value...
556 Views
SymBio Pharmaceuticals - Preparing to establish own sales organisation
SymBio announced in October that it has begun preparations to establish its own sales organisation to market Treakisym and other anticancer drugs...
53 Views
Japan Fortnightly Update: Spiked
SHORT-LIVED - The much-lauded 'breakout' in the Nikkei 225 (NKY INDEX) at the end of last month proved to be short-lived. As measured by Total...
359 Views